8-K: Atossa Therapeutics Faces Nasdaq Delisting Notice Due to Low Share Price

Atossa Therapeutics received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement for continued listing.

Summary

• Atossa Therapeutics received a notice from Nasdaq on February 21, 2025, stating that it doesn't meet the minimum bid price requirement of $1.00 per share for continued listing.
• The company's stock price remained below $1.00 for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
• Atossa has until August 20, 2025, to regain compliance by maintaining a minimum closing bid price of $1.00 per share for at least 10 consecutive business days.
• If compliance isn't achieved by August 20, 2025, the company may be eligible for an additional 180-day compliance period.
• The Nasdaq notice doesn't immediately affect the listing or trading of Atossa's common stock.
• Atossa intends to actively monitor its stock price and consider options to regain compliance.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice, indicating potential financial instability and loss of investor confidence. However, the company is taking steps to address the issue.

Positives

• The Nasdaq notice does not have an immediate effect on the listing or trading of Atossa's common stock.
• Atossa intends to actively monitor the bid price for its common stock and is committed to considering available options to regain compliance with the minimum bid price requirement.

Negatives

• Atossa Therapeutics is not in compliance with Nasdaq's minimum bid price requirement.
• The company's common stock price has been below $1.00 for 30 consecutive business days.

Risks

• Failure to regain compliance with Nasdaq Listing Rule 5550(a)(2) by August 20, 2025, could lead to delisting from the Nasdaq Capital Market.
• Delisting could negatively impact the company's stock price and investor confidence.

Future Outlook

Atossa intends to actively monitor the bid price for its common stock and is committed to considering available options to regain compliance with the minimum bid price requirement.

Management Comments

• Atossa is committed to considering available options to regain compliance with the minimum bid price requirement.

Industry Context

Delisting notices are not uncommon for smaller biotech companies, especially those with volatile stock prices or those undergoing significant clinical trials. Other companies in similar situations may consider reverse stock splits or other measures to boost their share price.

Comparison to Industry Standards

• Many small-cap biotech companies face similar challenges in maintaining Nasdaq listing compliance.
• Companies like Geron Corporation and Omeros Corporation have faced similar delisting warnings in the past and have implemented strategies such as reverse stock splits to regain compliance.
• The success of these strategies varies, and depends on the underlying financial health and future prospects of the company.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment if the company is delisted.
• Employees may face uncertainty regarding their job security if the company's financial situation worsens.
• The company's ability to raise capital and fund its operations may be negatively impacted.

Next Steps

• Atossa needs to monitor its stock price and consider options to regain compliance with Nasdaq's minimum bid price requirement.
• The company may explore strategies such as a reverse stock split or other measures to increase its share price.

Key Dates

Keywords

Nasdaq, delisting, minimum bid price, compliance, ATOS, Atossa Therapeutics, stock price